-
Featured Authors
-
Archives
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Latest From Biotech Now
What’s New in RNAi Therapeutics?
At the 16th Annual BIO CEO & Investor Conference, Monday morning’s therapeutic workshop, “Delivering the (RNAi) Goods,” featured a panel discussion moderated by Thomas Wei, senior research analyst at Jeffries LLC. The panel gave investors a peek into the novel approaches utilized by four leading companies in this area: Dicerna Pharmaceuticals, Arrowhead Research Corporation, Alnylam Pharmaceuticals, and Regulus Therapeutics. RNAi therapeutics, which include gene silencing, exon skipping, and mircroRNA therapy, are a promising area in the Read More >
4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14
The 16th Annual BIO CEO & Investor Conference opened with a fireside chat between Richard F. Pops, Chairman & Chief Executive Officer of Alkermes, and David Gluckman of Lazard. The candid discussion gave biotech CEOs a peek in to the story of Alkermes, yielding useful guidance on building a successful, agile company ready for a changing marketplace. Here are some of the highlights: Be world class in a specific area of science. “In our company, Read More >
Biotech Investors, Emerging Companies Bullish On 2014
The 16th BIO CEO & Investor Conference is off to a great start. This event has truly grown into a must attend for emerging companies and investors. This year, we have more than 1,300 participants, including more than 850 investors. In addition, we have helped to set up more than 1,700 partnering meetings for participants over the course of the conference. Our world-class partnering system, and the opportunity to hear from key industry leaders, is Read More >
A New Addition to Pennsylvania Bio’s Leadership Team
To effectively achieve our mission as the champion and advocate of biotechnology, BIO works with a broad network of organizations. Foremost among these relationships are the ones we possess with a broad network of state-based organizations known as the Council of State Bioscience Associations (CSBA). Pennsylvania Bio (PA Bio) has been a key ally to BIO and vocal advocate for state and federal public policy in support of the biotechnology industry since our inception. Just Read More >
FDA Week: For Biologics, A Name Isn’t Just A Name (Jim Greenwood op-ed)
What is in a name? Names help make medicinal products more easily distinguishable by doctors, pharmacists and patients. When you are talking about biologics, complex medicines that are manufactured using living organisms, and biosimilars, medicines that are similar to, but not the same as, innovator biologics, naming is a significant consideration. As a pathway for biosimilars approval is implemented, a clear priority should be to craft a naming convention that both contributes to patient safety Read More >
